Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for Breast Cancer

35 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Basic Science

    VICCBRE1445

    04/21/2014

    Optical Imaging of Breast Tumors

    Basic Science

    VICCBRE03103

    01/22/2004

    Breast Tissue/Body Fluids Repository (SPORE)

    Basic Science

    VCCBRE0057

    10/27/2000

    Nashville Breast Health Study

    Diagnostic

    VICCBRE0588

    03/07/2006

    MRI Evaluation Of Breast Tumor Growth And Treatment Response (SPORE)

    Other

    ECOGBREE2Z04-M

    06/11/2008

    Quality of LIfe in Younger Breast Cancer Survivors

    Other

    CTSUBREC70301-M

    06/11/2007

    Quality of Life, Employment and Informal Care Cost Analysis in Women Receiving Adjuvant Chemotherapy for Breast Cancer with 0-3 Positive Axillary Lymph Nodes

    Other

    VICCBRE0704

    02/21/2007

    Developing In-Vivo Models of Human Breast Cancer

    Other

    VICCBRE14107

    10/26/2005

    Breast Pathology Specimen Repository 050729

    Supportive Care

    VICCBRE1438

    06/19/2014

    A Randomized Trial Evaluating Bioimpedance Spectroscopy versus Tape Measurement in the Prevention of Lymphedema following Locoregional Treatment for Breast Cancer

    Treatment

    NRGBREB-51

    04/13/2016

    A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

    Treatment

    VICCBRE1599

    04/11/2016

    A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician's Choice for Metastatic Triple Negative Breast Cancer (mTNBC) - (KEYNOTE-119)

    Treatment

    VICCBRE1587

    04/05/2016

    An Open-Label, First -in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy in Subjects With Advanced Solid Tumors

    Treatment

    VICCBRE1562

    03/15/2016

    SOLAR-1: A Phase III Randomized Double-Blind, Placebo Controlled Study of Alpelisib in combination with Fulvestrant for Men and Postmenopausal Women with Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer which Progressed on or After Aromatase Inhibitor Treatment

    Treatment

    VICCBRE1557

    03/11/2016

    A Phase Ib Trial of LY2157299 (TGFβR1 Kinase Inhibitor) with Paclitaxel in Patients with Triple Negative Metastatic Breast Cancer

    Treatment

    VICCBRE1462

    03/08/2016

    A Phase I Dose Escalation Study of POL6326 with Eribulin in Patients with Relapsed Metastatic Breast Cancer

    Treatment

    VICCBRE1552

    02/02/2016

    A Randomized Phase II Study of Adjuvant Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination with Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)

    Treatment

    VICCBRE1546

    12/01/2015

    The Impact of HER2 Heterogeneity on the Treatment of Early- Stage HER2-Positive Breast Cancer: A Phase II Study of T- DM1 in Combination with Pertuzumab in the Preoperative Setting

    Treatment

    VICCPHI1588

    11/27/2015

    A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors

    Treatment

    VICCHEMP1558

    10/09/2015

    A Phase 1a/1b, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies

    Treatment

    VICCBRE1543

    09/30/2015

    A Phase III, Multicenter, Randomized, Placebo-Controlled Study of MPDL3280A (Anti−PD-L1 Antibody) in Combination with Nab-Paclitaxel Compared with Placebo with Nab-Paclitaxel for Patients with Previously Untreated Metastatic Triple -Negative Breast Cancer

    Treatment

    VICCPHI1528

    07/22/2015

    A Multi-Center Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with MEDI4736, in Subjects with Relapsed or Refractory Solid Tumors

    Treatment

    VICCBRE1374

    06/15/2015

    Phase Ib/II Trial of Taselisib (GDC-0032), a PI3K Inhibitor, in Combination with Enzalutamide in Patients with Androgen Receptor Positive Triple Negative Metastatic Breast Cancer

    Treatment

    VICCBRE1480

    03/31/2015

    A Randomized, Multicenter, Open Label Study of MM-302 plus Trastuzumab vs. Chemotherapy of Physician's Choice plus Trastuzumab in Anthracycline Naive Patients with Locally Advanced/Metastatic HER2-Positive Breast Cancer

    Treatment

    VICCBRE1246

    03/13/2015

    Enhancing Efficacy of Chemotherapy in Triple-Negative/Basal-Like Breast Cancers by Targeting Macrophages: A Phase Ib/II Study of PLX3397 and Eribulin in Patients with Metastatic Breast Cancer

    Treatment

    VICCBRE1430

    08/12/2014

    A Phase 2, Multicenter, Open-label Study to Assess the Efficacy and Safety of Enzalutamide with Trastuzumab in Subjects with HER2+ AR+ Metastatic or Locally Advanced Breast Cancer

    Treatment

    VICCBRE1391

    04/24/2014

    A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib versus Physician's Choice in Previously-Treated, HER2-Negative, Germline BRCA Mutation-Positive Breast Cancer Patients

    Treatment

    VICCBRE1320

    08/16/2013

    A Phase Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0032 in Combination with Either Docetaxel or Paclitaxel in Patients with HER2-Negative Locally Recurrent or Metastatic Breast Cancer or Non-Small Cell Lung Cancer

    Treatment

    VICCBRE1298

    04/19/2013

    A Safety and Efficacy Study of Intra-Operative Radiation Therapy (IORT) Using the Xoft? Axxent? eBx System at the Time of Breast Conservation Surgery for Early Stage Breast Cancer

    Treatment

    VICCBREP12116

    03/25/2013

    An Open-Label, Phase IA/IB/IIA Study of GDC-810 Single Agent or in Combination With Palbociclib and/or an LHRH Agonist in Women with Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

    Treatment

    VICCPHI1248

    10/12/2012

    An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC0032 in Patients with Locally Advanced or Metastatic Solid Tumors and in Combination with Endocrine Therapy in Patients with Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer

    Treatment

    CTSUBRENB-43-M

    04/26/2012

    A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy

    Treatment

    CTSUNSABPBREB-47-M

    04/26/2012

    A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer 

    Treatment

    CTSUBRENCCTGMA32-M

    04/23/2012

    A Phase III Randomized Trial of Metformin versus Placebo on Recurrence and Survival in Early Stage Breast Cancer

    Treatment

    CTSUBRES1007-M

    05/25/2011

    Phase III randomized trial of standard adjuvant endocrine therapy +/- chemo in patients with 1-3 positive nodes, hormone receptor positive and Her2 negative breast cancer with recurrence score (RS) of 25 or less

    Treatment

    CTSUBREC40603-M

    12/07/2010

    Randomized Phase II 2 X 2 Factorial Trial Of The Addition Of Carboplatin +/- Bevacizumab To Neoadjuvant Weekly Paclitaxel Followed By Dose-Dense AC In Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer


    Print this page for your doctor